influenza vaccine + COVID vaccine

The influenza vaccine + COVID vaccine refers to investigational combination vaccines designed to provide simultaneous protection against seasonal influenza and SARS-CoV-2 in a single injection, primarily targeting adults aged 50 years and older. These candidates combine licensed influenza vaccines—such as protein-based trivalent formulations like Fluzone High-Dose (inactivated) or Flublok (recombinant)—with adjuvanted recombinant protein-based COVID-19 vaccines like Novavax's NVX-CoV2373, leveraging nanoparticle technology and Matrix-M adjuvant to elicit immune responses via antigen presentation and antibody production against influenza hemagglutinin and SARS-CoV-2 spike protein. Developers including Sanofi, Novavax, Moderna (mRNA-1083), and Pfizer/BioNTech are advancing these non-mRNA and mRNA-based versions to simplify vaccination, improve compliance, and potentially enhance uptake, with ongoing phase 1/2/3 trials evaluating safety, immunogenicity, and non-inferiority to co-administered separate vaccines.[1][2][3][4][5]

Other names

combo flu-COVID vaccinecombination influenza-COVID vaccineCOVID-flu combo vaccine